August 8, 2011

PositiveID Corporation Appoints Pietro Galassetti, MD, PhD to Its Scientific Advisory Board

Dr. Galassetti is World-Renowned for His Research on Non-Invasive Glucose Detection Through Breath Analysis

Dr. Galassetti to Contribute to Development of PositiveID's Easy Check Breath Glucose Detection Device

DELRAY BEACH, Fla., Aug. 8, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (Nasdaq:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today that it has appointed Pietro Galassetti, MD, PhD, to its Scientific Advisory Board. Dr. Galassetti is Associate Professor of Pediatrics and Pharmacology at the University of California, Irvine ("UCI"), where he also serves as the Director of the Bionutrition/Metabolism Core at the Institute for Clinical and Translational Science, and as Associate Director of the Pediatric Exercise Research Center. In his role as scientific advisor to PositiveID, Galassetti will contribute his expertise on breath analysis to the development of the Company's Easy Check™ non-invasive breath glucose detection device.

Galassetti has focused on developing a novel technology to measure non-invasively a broad range of metabolic variables through exhaled breath analysis, in collaboration with the UCI department of chemistry. A number of previously unstudied gases present in human breath at extremely low concentrations correlated with several key metabolic indicators, including plasma glucose, insulin, lipids, ketones and inflammatory markers, promise the near-future evolution of these measurements into clinically applicable devices. The author of over 70 peer-reviewed publications, over the past decade Galassetti has developed several parallel lines of research with the common theme of the prevention and monitoring of progression of complications in dysmetabolic states, including pediatric obesity, metabolic syndrome, and type 1 and type 2 diabetes. 

The recipient of several scientific national awards, Galassetti is a member of the editorial board of the Journal of Applied Physiology, acts as a reviewer for about 20 scientific journals, and as a grant reviewer for the NIH, the Juvenile Diabetes Foundation and several international scientific foundations.

Scott R. Silverman, Chairman and CEO of PositiveID, said, "It is an honor to have Dr. Galassetti, a world-renowned scientist in the field of breath analysis for blood glucose levels, join our scientific advisory board. We will work with Dr. Galassetti and utilize his experiences and expertise to improve our research and development of our Easy Check breath glucose detection device."

For more information on Galassetti, including links to his profile and research on non-invasive glucose analysis using exhaled breath, please visit http://www.faculty.uci.edu/profile.cfm?faculty_id=5236. Additional information on Galassetti's research can be found at http://www.ncbi.nlm.nih.gov/sites/entrez?dispmax=25&db=PubMed&pmfilter_EDatLimit=added%20to%20PubMed%20in%20the%20last%200%20i&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=galassetti%20pr&doptcmdl=DocSum.

The lab prototype of the Company's Easy Check non-invasive breath glucose detection device unit utilizes a single-use capsule containing a proprietary reagent that mixes with a person's exhaled breath and triggers a chemical reaction that can be immediately measured by an advanced optical sensor and state-of-the-art microprocessor to accurately correlate to blood glucose levels. The goal of the Company's Easy Check device is to eliminate a patient's need to prick his or her finger multiple times per day in order to get a blood sugar reading.

About PositiveID Corporation

PositiveID Corporation develops unique medical devices and biological detection systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com

The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID's future expectations, including Galassetti's ability in his role as scientific advisor to PositiveID, to contribute his expertise on breath analysis to the development of the Company's Easy Check non-invasive breath glucose detection device; the likelihood that a number of previously unstudied gases present in human breath at extremely low concentrations correlated with several key metabolic indicators, including plasma glucose, insulin, lipids, ketones and inflammatory markers, promise the near-future evolution of these measurements into clinically applicable devices; the likelihood that we will work with Galassetti and utilize his experiences and expertise to improve our research and development of our Easy Check breath glucose detection device; the ability of the lab prototype of the Company's Easy Check non-invasive breath glucose detection device unit to utilize a single-use capsule containing a proprietary reagent that mixes with a person's exhaled breath and triggers a chemical reaction that can be immediately measured by an advanced optical sensor and state-of-the-art microprocessor to accurately correlate to blood glucose levels; the likelihood that Easy Check will eliminate a patient's need to prick his or her finger multiple times per day in order to get a blood sugar reading; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to continue the development of and successfully commercialize Easy Check, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Q filed on May 13, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: Allison Tomek

         561-805-8000

         atomek@positiveidcorp.com



         Dan Schustack

         CEOcast

         212-732-4300

         dschustack@ceocast.com

PositiveID Corporation Logo

Source: PositiveID Corporation

News Provided by Acquire Media


Close window | Back to top

Copyright 2014 PositiveID Corporation